Synergistic anti-viral effect of oxanosine and ddI against human immunodeficiency virus.
The combined effect against human immunodeficiency virus (HIV) of oxanosine and 2'3'-dideoxyinosine (ddI) has been evaluated by the production of viral particles, the expression of viral antigens on cell surfaces, and the amount of viral genome integrated in the host cells. Oxanosine alone has no effect on HIV replication up to 100 microg/ml, however, in the presence of ddI, oxanosine revealed concentration dependent inhibition against HIV without cytotoxicity.
Nakamura
Mariko
M
Department of Microbiology, The Jikei University School of Medicine 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 Japan. nakamura@jikei.ac.jp
Ogawa
Tomoo
T
Yokono
Akira
A
Nakamori
Shogo
S
Ohno
Tsuneya
T
Umezawa
Kazuo
K
D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology*; D002460:Cell Line; D016049:Didanosine / Q000737:chemistry / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006678:HIV / Q000187:drug effects* / Q000235:genetics / Q000276:immunology; D006801:Humans; D012263:Ribonucleosides / Q000737:chemistry / Q000494:pharmacology*
D000998:Antiviral Agents; D012263:Ribonucleosides; C032886:oxanosine; D016049:Didanosine